Browsing by Subject "HCC"
Now showing items 1-3 of 3
-
Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cells
(2015-01)Hepatocellular carcinoma (HCC) is characterized by limited response to current drug therapies. Here, we report that SC66, a novel AKT inhibitor, reduced cell viability in a dose- and time-dependent manner, inhibited colony ... -
Targeted therapy for hepatocellular carcinoma: novel agents on the horizon
(2012-03)Hepatocellular carcinoma (HCC) is the most common liver cancer, accounting for 90% of primary liver cancers. In the last decade it has become one of the most frequently occurring tumors worldwide and is also considered to ... -
Yttrium-90 Radioembolization in Patients with Hepatocellular Carcinoma Who have Previously Received Sorafenib
(2013-11)Purpose: Yttrium-90 radioembolization (RE) is a locoregional therapy option for hepatocellular carcinoma (HCC). Sorafenib is a multikinase inhibitor used in HCC that can potentially affect the efficacy of RE by altering ...